

In claim 14, delete "3" and insert in place thereof --13--

In claim 15, delete "4" and insert in place thereof --14--

In claim 16, delete "5" and insert in place thereof --15--

Rewrite claim 17 as follows:

A  
17. (Amended) The method of claim [5] 15 wherein [Y is O] Y<sup>1</sup> is Cl or trifluoromethyl, Z is =O and X is selected from the group consisting of alkoxy and amido radicals.

In claim 18, delete "1" and insert in place thereof --11--

In claim 19, delete "7" and insert in place thereof --17--

In claim 20, delete "1" and insert in place thereof --11--


In claim 21 at lines 26 and 27 of page 32, delete "B is not substituted with a pendant heteroatom-containing radical and Z is =O, then x is not -OR<sup>4"</sup> and insert in place thereof --Z is =O, then X is not -OR<sup>4"--</sup>

In claim 25, line 1, add "or glaucoma" after --hypertension--

In claim 22 delete "cyclopentane heptenoic acid-5-cis-2-(3 $\alpha$ -hydroxy-4-meta-chloro-phenoxy-1-trans-butenyl)-3, 5-dihydroxy, [1 $\alpha$ , 2 $\beta$ , 3 $\alpha$ , 5 $\alpha$ ];"

Add new claims:

A  
26. (New Claim) A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein R<sup>1</sup> =hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C<sub>1</sub>-C<sub>12</sub> alkyl cycloalkyl or aryl; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

27. (New Claim) The method of claim 1, wherein R<sup>1</sup> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub> and C(CH<sub>3</sub>)<sub>3</sub>.

28. (New Claim) The method of claim 1, wherein R<sup>1</sup> is selected from the group consisting of Na<sup>+</sup> and CH<sub>3</sub>N<sup>+</sup>(CH<sub>2</sub>OH)<sub>3</sub>.

29. (New Claim) The method of claim 1, wherein R<sup>2</sup> is Cl.


30. (New Claim) The method of claim 2, wherein R<sup>2</sup> is CF<sub>3</sub>.

31. (New Claim) The method of claim 1, wherein between about 0.001 and about 1000 µg/eye of a compound of formula (I) is administered.

32. (New Claim) The method of claim 6, wherein between about 0.01 and about 100 µg/eye of a compound of formula (I) is administered.

33. (New Claim) The method of claim 6, wherein between about 0.05 and about 10 µg/eye of a compound of formula (I) is administered.

34. (New Claim) A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising a therapeutically effective amount of a compound of formula:



wherein: R<sup>1</sup> = hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C<sub>1</sub>-C<sub>12</sub> alkyl, cycloalkyl or aryl; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

35. (New Claim) The composition of claim 9, wherein R<sup>1</sup> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub> and C(CH<sub>3</sub>)<sub>3</sub>.

36. (New Claim) The composition of claim 9, wherein R<sup>1</sup> is selected from the group consisting of Na<sup>+</sup> and CH<sub>3</sub>N<sup>+</sup>(CH<sub>2</sub>OH)<sub>3</sub>.

37. (New Claim) The composition of claim 9, wherein R<sup>2</sup> is Cl.


38. (New Claim) The composition of claim 9, wherein R<sup>2</sup> is CF<sub>3</sub>.

39. (New Claim) The composition of claim 9, wherein between about 0.001 and about 100 µg/eye of a compound of formula (I) is administered.

40. (New Claim) The composition of claim 14, wherein between about 0.01 and about µg/eye of a compound of formula (I) is administered.

41. (New Claim) The composition of claim 15, wherein between about 0.05 and about 10 µg/eye of a compound of formula (I) is administered.

42. (New Claim) A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:




wherein: R<sup>1</sup> = a pharmaceutically acceptable ester moiety; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

43. (New Claim) The method of claim 17, wherein R<sup>2</sup> is Cl.

44. (New Claim) The method of claim 17, wherein R<sup>2</sup> is CF<sub>3</sub>.

45. (New Claim) The method of claim 17, wherein between about 0.001 and about 1000 µg/eye of a compound of formula (I) is administered.

46. (New Claim) A method of treating ocular hypertension or glaucoma which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of the formula




wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, X is a radical selected from the group consisting of -OR<sup>4</sup> and -N(R<sup>4</sup>)<sub>2</sub> wherein R<sup>4</sup> is selected from the group consisting of hydrogen, a lower alkyl radical having from one to six




carbon atoms, R<sup>5</sup>-C- or R<sup>5</sup>-O-C- wherein R<sup>5</sup> is a lower alkyl radical having from one to six carbon atoms; Z is =O or represents 2 hydrogen radicals; one of R<sub>1</sub> and R<sub>2</sub> is =O, -OH or a -O(CO)R<sub>6</sub> group, and the other one is -OH or -O(CO)R<sub>6</sub>, or R<sub>1</sub> is =O and R<sub>2</sub> is H, wherein R<sub>6</sub> is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or -(CH<sub>2</sub>)<sub>m</sub>R<sub>7</sub> wherein m is 0-10, and R<sub>7</sub> is a cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl or heteroaryl radical, as defined above, or a pharmaceutically-acceptable salt thereof, provided however that when Z is =O, then X is not -OR<sup>4</sup>.

47. (New Claim) The method of claim 46 wherein said compound is represented by the formula




wherein hatched lines indicate the  $\alpha$  configuration and solid triangles indicate the  $\beta$  configuration.

746. (New Claim) The method of claim 7 wherein said compound is represented by the formula



846. (New Claim) The method of claim 7 wherein said compound is represented by the formula



and the 9- and/or 11- and/or 15 esters, thereof.

950. (New Claim) The method of claim 8 wherein Z is =O and X is  $-\text{N}(\text{R}^4)_2$ .